Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jun-Jul;34(6-7):581-6.
doi: 10.1016/j.addbeh.2009.03.014. Epub 2009 Mar 24.

Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence

Kyle M Kampman  1 , Helen M Pettinati, Kevin G Lynch, Hu Xie, Charles Dackis, David W Oslin, Thorne Sparkman, Tiffany Sharkoski, Charles P O'Brien
Affiliations
Randomized Controlled Trial

Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence

Kyle M Kampman et al. Addict Behav. 2009 Jun-Jul.

Abstract

Objectives: This trial compared the efficacy of acamprosate, started at the beginning of detoxification, to acamprosate started at the completion of detoxification, in the treatment of alcohol dependence.

Methods: This biphasic clinical trial consisted of a randomized, double-blind, placebo-controlled Detoxification Phase (DP), followed by a 10-week open-label Rehabilitation Phase (RP). Forty alcohol dependent patients were randomly assigned to receive either 1998 mg of acamprosate daily, or matching placebo, during the DP (5-14 days). After completing detoxification, all patients received open label acamprosate (1998 mg daily) in the RP. Outcome measures during the DP included: treatment retention, alcohol withdrawal, alcohol consumption, and oxazepam used. Outcome measures during the RP included: treatment retention and alcohol consumption.

Results: There were no significant outcome differences between acamprosate and placebo-treated patients during the DP. Patients given acamprosate, compared to placebo, during the DP drank more alcohol in the RP.

Conclusions: Starting acamprosate at the beginning of detoxification did not improve DP outcomes. Starting acamprosate after detoxification was completed was associated with better drinking outcomes during subsequent alcohol rehabilitation treatment.

PubMed Disclaimer

References

    1. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcoholism: Clinical & Experimental Research. 1998;22(4):810–814. - PubMed
    1. Aubin H, Lehert P, Beaupere B, Jacquemin F, Barrucand D. Tolerance de l’acamprosate aux medicaments du sevrage d’alcool. Essai multicentrique sur 591 alcooliques en sevrage. Alcoologie. 1994;16:32–41.
    1. Baekeland F, Lundwall L, Shanahan T. Correlates of Subject attrition in the outpatient treatment of alcoholism. Journal of Nervous and Mental Diseases. 1973;157:99–107. - PubMed
    1. Boeijinga PH, Parot P, Soufflet L, Landron F, Danel T, Gendre I, et al. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology. 2004;50(1):71–77. - PubMed
    1. Cockroft D, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. - PubMed

Publication types

MeSH terms